Vimarsana
Biggest News Aggregation in the World

Page 2 - Sun Xin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sun Xin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sun Xin Today - Breaking & Trending Today

Access to Chinese Web site curbed for offshore users - Vimarsana News

Access to Chinese Web site curbed for offshore users

Bringing Taiwan to the World and the World to Taiwan

ED. FRONTLINES: Survey of Asian Americans during heightened prejudice - Vimarsana News

ED. FRONTLINES: Survey of Asian Americans during heightened prejudice

John Richard Schrock" /> John Richard Schrock By JOHN RICHARD SCHROCKA&

Award-winning Chinese mathematician Sun Xin returns from US to work at Peking University - Vimarsana News

Award-winning Chinese mathematician Sun Xin returns from US to work at Peking University

Sun Xin joins long line of US-based ethnic Chinese scientists who have switched their affiliation from American to Chinese institutions.

Source: scmp.com
How will Chinese universities respond to the rise of ChatGPT? - Vimarsana News

How will Chinese universities respond to the rise of ChatGPT?

AI-powered tools without multiple mechanisms of censorship are unlikely to be allowed on mainland, expert says

Ocumension OT-401 (Product name: YUTIO), a treatment for chronic non-infectious uveitis officially approved for marketing by the National Medical Products Administration - Vimarsana News

Ocumension OT-401 (Product name: YUTIO), a treatment for chronic non-infectious uveitis officially approved for marketing by the National Medical Products Administration

BEIJING, June 23, 2022 /PRNewswire/ --Ocumension Therapeutics 1477.HKannounced that the New Drug Application (NDA) for the core product in its pipeline, OT-401 (Sterile non-bioerodible intravitreal implant, Product name: YUTIO), was officially approved by the National Pharmaceutical Administration (NMPA) for the treatment of chronic non-infectious uveitis involving the posterior segment of the eye (chronic NIU-PS). This is the first new drug in Ocumension's pipeline to be approved for marketing and is currently the potential best-in-class therapy for the treatment of this indication in Chi...